ZELAPAR Drug Patent Profile
✉ Email this page to a colleague
When do Zelapar patents expire, and what generic alternatives are available?
Zelapar is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in ZELAPAR is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zelapar
A generic version of ZELAPAR was approved as selegiline hydrochloride by MLV on April 1st, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZELAPAR?
- What are the global sales for ZELAPAR?
- What is Average Wholesale Price for ZELAPAR?
Summary for ZELAPAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 97 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,912 |
| Drug Prices: | Drug price information for ZELAPAR |
| What excipients (inactive ingredients) are in ZELAPAR? | ZELAPAR excipients list |
| DailyMed Link: | ZELAPAR at DailyMed |
Recent Clinical Trials for ZELAPAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of South Florida | Phase 4 |
| Bausch Health Americas, Inc. | Phase 4 |
| Parkinson's Disease and Movement Disorder Center of Boca Raton | Phase 4 |
Pharmacology for ZELAPAR
| Drug Class | Monoamine Oxidase Inhibitor Monoamine Oxidase Type B Inhibitor |
| Mechanism of Action | Monoamine Oxidase Inhibitors Monoamine Oxidase-B Inhibitors |
US Patents and Regulatory Information for ZELAPAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | ZELAPAR | selegiline hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021479-001 | Jun 14, 2006 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZELAPAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | ZELAPAR | selegiline hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021479-001 | Jun 14, 2006 | ⤷ Subscribe | ⤷ Subscribe |
| Bausch | ZELAPAR | selegiline hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021479-001 | Jun 14, 2006 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZELAPAR
See the table below for patents covering ZELAPAR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Cyprus | 2157 | Preparation of pharmaceutical and other matrix systems by solid-state dissolution | ⤷ Subscribe |
| United Kingdom | 9504201 | ⤷ Subscribe | |
| Germany | 69614096 | ⤷ Subscribe | |
| China | 1085081 | ⤷ Subscribe | |
| Australia | 646428 | ⤷ Subscribe | |
| Germany | 69326063 | ⤷ Subscribe | |
| Chile | 2004001180 | ⤷ Subscribe | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
